Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc.ELOX · Entity 7180 | Director | May 20, 2020 | May 22, 2020 |
| European Biotech Acquisition Corp.EBAC · Entity 139403 | Director | March 15, 2021 | March 15, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eloxx Pharmaceuticals, Inc.
Report date May 20, 2020 · Filed May 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.39 · Expires 2030-05-20 | Direct | 20,000 |
Reported balance
After 2020-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-20 · Grant · Acquired 20,000 · Balance 20,000 F1: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 20, 2021 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 20, 2021 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.
European Biotech Acquisition Corp.
Report date March 15, 2021 · Filed March 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | IndirectIndirect | Not disclosed |
Reported balance
Holding disclosure · report date 2021-03-15 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-253220) (the "Registration Statement") under the heading "Description of Securities - Founder Shares", the Class B ordinary shares will automatically convert into Class A ordinary shares on a one-for-one basis on the first business day following the consummation of the issuer's initial business combination, subject to adjustment as described in the Registration Statement. The Class B ordinary shares have no expiration date. F2: Shares reported above are held in the name of LSP Sponsor EBAC B.V. LSP Management Group B.V. is the majority owner of LSP Sponsor EBAC B.V. and as such, LSP Management Group B.V. has voting and investment discretion with respect to the shares held of record by our sponsor and may be deemed to have shared beneficial ownership of the shares held by LSP Sponsor EBAC B.V. The reporting person is a director of LSP Management Group B.V. and has voting and investment discretion with respect to the shares held by LSP Management Group B.V. and may be deemed to have indirect shared beneficial ownership of the shares held by LSP Sponsor EBAC B.V. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-253220) (the "Registration Statement") under the heading "Description of Securities - Founder Shares", the Class B ordinary shares will automatically convert into Class A ordinary shares on a one-for-one basis on the first business day following the consummation of the issuer's initial business combination, subject to adjustment as described in the Registration Statement. The Class B ordinary shares have no expiration date.
F2: Shares reported above are held in the name of LSP Sponsor EBAC B.V. LSP Management Group B.V. is the majority owner of LSP Sponsor EBAC B.V. and as such, LSP Management Group B.V. has voting and investment discretion with respect to the shares held of record by our sponsor and may be deemed to have shared beneficial ownership of the shares held by LSP Sponsor EBAC B.V. The reporting person is a director of LSP Management Group B.V. and has voting and investment discretion with respect to the shares held by LSP Management Group B.V. and may be deemed to have indirect shared beneficial ownership of the shares held by LSP Sponsor EBAC B.V. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2020 Filed May 22, 2020 20:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $3.39 | $0.00 |
DisclosureSEC source: 0001415889-20-001298 · form4-05222020_040501.xml · derivative · entry 1 Kleijwegt Martijn · CIK 0001726016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-20 F1 · derivative.exercise_date: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 20, 2021 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. Read SEC document |
| May 29, 2019 Filed May 30, 2019 18:06 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $9.02 | $0.00 |
DisclosureSEC source: 0001415889-19-000630 · form4-05302019_110553.xml · derivative · entry 1 Kleijwegt Martijn · CIK 0001726016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-29 F1 · derivative.exercise_date: One half (1/2) of the shares underlying the option shall vest on May 29, 2020 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 22:12 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $23.27 | $0.00 |
DisclosureSEC source: 0001209191-18-038656 · doc4.xml · derivative · entry 1 Kleijwegt Martijn · CIK 0001726016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-06-15 F1 · derivative.exercise_date: One half (1/2) of the shares underlying the option shall vest on June 15, 2019 (the "Cliff Vesting Date"), the remainder of the grant shall vest in equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. Read SEC document |
| April 30, 2018 Filed May 1, 2018 20:32 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | PurchaseCommon Stock | 300,000 | $9.75 | $2,925,000.00 |
DisclosureSEC source: 0001209191-18-027108 · doc4.xml · nonDerivative · entry 1 Kleijwegt Martijn · CIK 0001726016 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LSP investment fund Disclosed balance after: 2,953,673 F1 · kind: Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018. F2 · ownership.nature: Represents shares of the Issuer held by LSP V Cooperatieve U.A. ("LSP V"). LSP V Management B.V. ("LSP V Management") is the director and manager of LSP V. Mr. Kleijwegt is a Managing Director of LSP V Management. By virtue of this relationship, Mr. Kleijwegt may be deemed to share voting and dispositive power with respect to the shares held by LSP V. Mr. Kleijwegt disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.